Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

One of several anti-CD38 antibodies in pipeline

- PMLiVE

Amazon’s Alexa to provide NHS health information

Launched by new NHSX digital change division

- PMLiVE

Alnylam gains key NICE approval for Onpattro

Important milestone for company's first product

Battling breast cancer with precision medicine (Part 2)

Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Blue Latitude Health

Corporate event food. How to get it right

Food affects our mood. When we are hungry, we are more likely to be irritable and unhappy. On the other hand, being full makes us happy and relaxed. But, with...

Apex Events and Exhibitions

How patient insights were brought to life with graphic novel outputs

Research Partnership's client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks; the main burden of disease is not just...

Inizio

Research Partnership publishes new patient Living with Ankylosing Spondylitis & nr-axSpA EU & US 2019 reports

Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients...

Inizio

- PMLiVE

BioNTech raises €290m for mRNA cancer vaccine platform

Funds will help lead melanoma candidate progress

Insight full – our short survey

There is still time to shift the balance in our survey. Let us know how satisfied you are with yours?

Page & Page Health

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Treatment can help patients with advanced disease, companies say

- PMLiVE

UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

Pilot much more to industry liking, but devil will be in detail

- PMLiVE

Boehringer tests speech as early warning for CNS diseases

Company extends foray into digital health innovation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links